StudyFinder

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Recruiting

ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NINDS StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.

I'm interested

This study is NOT accepting healthy volunteers

Stroke

Apixaban, Aspirin, Atrial Cardiopathy, Clinics and Surgery Center (CSC), Cryptogenic stroke, Ischemic stroke

Anna Brauch - brauc019@umn.edu
Benjamin Miller
Phase III
STUDY00001759
NCT03192215
See this study on ClinicalTrials.gov

Back